Detalhe da pesquisa
1.
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.
J Pathol
; 256(4): 388-401, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34897700
2.
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.
BMC Cancer
; 19(1): 611, 2019 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31227025
3.
Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
Clin Cancer Res
; 26(20): 5400-5410, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32737030
4.
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Integr Cancer Ther
; 16(2): 165-175, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27627986
5.
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Breast Care (Basel)
; 11(5): 315-322, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27920623